Why the Nagoya Protocol Exists
For most of the twentieth century, the genetic resources of the world's most biodiverse nations were treated, in practice, as a global commons. Researchers, pharmaceutical companies, and agricultural breeders could collect plant material, return to their laboratories, and develop commercially valuable products without any legal obligation to share the resulting benefits with the countries or communities that had stewarded those biological materials for generations. This was not illegal under the frameworks then in place - it was simply the way science worked.
The injustice of this arrangement became increasingly apparent as the commercial value of biodiversity became clearer. The 1992 Convention on Biological Diversity (CBD) established for the first time that countries hold sovereign rights over their genetic resources [1]. But the CBD contained no binding mechanism to ensure that those rights translated into real benefits. The gap between principle and practice remained wide.
The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilisation, adopted in 2010 and entering into force in October 2014, was the international community's answer to that gap [2]. As of 2024, 140 countries had ratified the Protocol, creating a binding international regime governing how biological genetic resources are accessed and how benefits from their use must be shared.
The Three Pillars of Compliance
The Protocol's architecture rests on three interdependent legal instruments that must be obtained before any collection of genetic resources for research or commercial purposes:
Prior Informed Consent (PIC) - Formal written permission from the competent national authority - in Madagascar, the Direction G-n-rale de l'Environnement et des For-ts (DGEF) within the Ministry of Environment and Sustainable Development - before any collection takes place. PIC is not retroactive; it must be obtained in advance [3].
Mutually Agreed Terms (MAT) - A contractual agreement negotiated between the provider country and the resource user, specifying what the genetic resources may be used for, what benefit-sharing obligations apply, and what monitoring and reporting requirements apply. MAT turns the principle of benefit-sharing into enforceable obligations [3].
Internationally Recognised Certificate of Compliance (IRCC) - A certificate issued by the national ABS Clearing-House and registered on the CBD's global ABS Clearing-House platform. The IRCC provides internationally verifiable proof that collection was lawful. For commercial users, it is the primary legal shield against downstream liability [4].
EU ABS Regulation 511/2014: Compliance in Practice
For European companies - and for any company seeking to sell products in European markets - the Nagoya Protocol is operationalised through EU Regulation 511/2014, which entered into force in October 2014 alongside the Protocol itself [5]. This Regulation requires that companies accessing genetic resources for research and development purposes exercise due diligence to establish that resources were accessed lawfully, maintain documentation, and transfer compliance obligations to downstream users.
The due diligence requirement is not a box-ticking exercise. It requires that access occurred with PIC, that MAT was established, and that these instruments are traceable through the supply chain. The European Commission maintains a register of recognised best-practice standards for due diligence compliance, and Member State competent authorities have powers to inspect, audit, and impose penalties for non-compliance [5].
The practical consequence for the life sciences sector is that any dataset, compound library, or biological material derived from a Nagoya-signatory country without a complete and traceable compliance record carries regulatory risk that can block product development pipelines, void licences, and expose companies to enforcement action in European markets.
Madagascar's National ABS Framework
Madagascar ratified the Nagoya Protocol in 2014. Its primary domestic implementing instrument is Decree No. 2017-066 on Access to Biological Genetic Resources and Associated Traditional Knowledge, which establishes the DGEF as the national competent authority and sets out the procedural requirements for PIC and MAT [6].
The Decree requires that all genetic resource access agreements include formal benefit-sharing obligations, that instruments be registered with the ABS Clearing-House before biological material or data leaves Madagascar, and that enforcement mechanisms - including permit revocation and repatriation of illegally exported material - be available to authorities.
A constitutional review process in 2025-2026 has introduced a period of legislative revision. IsoGentiX has formally requested engagement with the relevant authorities on interim compliance guidance and has expressed its commitment to participating constructively in the redrafting process - ensuring that the eventual revised framework is both constitutionally sound and practically effective for compliant operators [7].
Why Compliance is a Commercial Asset, Not Just a Legal Cost
The instinctive framing in commercial contexts is that regulatory compliance is a cost of doing business. For Nagoya, the opposite is closer to the truth. A complete, blockchain-auditable compliance record transforms biological data from a legally ambiguous asset into a commercially deployable one. Without it, pharmaceutical companies, agritech firms, and AI biology platforms cannot use the data without incurring liability. With it, they can.
This asymmetry creates a structural premium for Nagoya-compliant data suppliers. IsoGentiX's compliance architecture - covering PIC, MAT, IRCC, and Hyperledger Fabric blockchain-registered provenance for every specimen - is not an overhead on the business model. It is the foundation of its commercial value.